GLP-1 receptor agonists (GLP-1RAs) such as liraglutide and semaglutide, initially used in the treatment of T2DM, are currently approved by the FDA for weight management and have been gaining an increasingly strong position on the anti-obesity drug market. The gene discussed is GLP1R; the disease is Obesity.